Companies › Orion Corporation, Orion Pharma
3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ODM-212 Unclear mechanism | – | Phase 1 | Solid Tumours; Mesothelioma | Dec 2027 |
| ODM-216 | – | Phase 1 | Advanced Solid Tumors Cancer | Jan 2028 |
| ODM-208 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitor | – | Phase 1 | Prostate Cancer Metastatic | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03436485 | ODM-208 | Phase 1 | Prostate Cancer Metastatic | Oncology | Oct 2026 |
| NCT06725758 | ODM-212 | Phase 1 | Solid Tumours | Oncology | Dec 2027 |
| NCT07805252 | ODM-216 | Phase 1 | Advanced Solid Tumors Cancer | Oncology | Jan 2028 |
| NCT07563738 | ODM-212 | Phase 1 | Mesothelioma | Oncology | Sep 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.